[go: up one dir, main page]

ES2114887T3 - Utilizacion de proteasa nexina-i que induce la cicatrizacion de heridas. - Google Patents

Utilizacion de proteasa nexina-i que induce la cicatrizacion de heridas.

Info

Publication number
ES2114887T3
ES2114887T3 ES91907406T ES91907406T ES2114887T3 ES 2114887 T3 ES2114887 T3 ES 2114887T3 ES 91907406 T ES91907406 T ES 91907406T ES 91907406 T ES91907406 T ES 91907406T ES 2114887 T3 ES2114887 T3 ES 2114887T3
Authority
ES
Spain
Prior art keywords
wound healing
nexin
utilization
inducing wound
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907406T
Other languages
English (en)
Inventor
Randy W Scott
Richard A Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2114887T3 publication Critical patent/ES2114887T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA PROMOVER LA CURACION DE HERIDAS CON UNA COMPOSICION QUE CONTIENE PROTEASA NEXIN-I (PN-I). SE PRESENTAN COMPOSICIONES QUE COMPRENDEN PN-I UNIFORMEMENTE DISPERSO A TRAVES DE UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.
ES91907406T 1990-04-05 1991-04-01 Utilizacion de proteasa nexina-i que induce la cicatrizacion de heridas. Expired - Lifetime ES2114887T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/505,442 US5112608A (en) 1987-03-13 1990-04-05 Use of protease nexin-I to mediate wound healing

Publications (1)

Publication Number Publication Date
ES2114887T3 true ES2114887T3 (es) 1998-06-16

Family

ID=24010332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907406T Expired - Lifetime ES2114887T3 (es) 1990-04-05 1991-04-01 Utilizacion de proteasa nexina-i que induce la cicatrizacion de heridas.

Country Status (9)

Country Link
US (1) US5112608A (es)
EP (1) EP0556178B1 (es)
JP (1) JP3150338B2 (es)
AT (1) ATE163861T1 (es)
AU (1) AU647120B2 (es)
CA (1) CA2079783A1 (es)
DE (1) DE69129071T2 (es)
ES (1) ES2114887T3 (es)
WO (1) WO1991015233A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8602626D0 (en) * 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
US5206017A (en) * 1986-06-03 1993-04-27 Incyte Pharmaceuticals, Inc. Use of protease nexin-I as an antiinflammatory
US5326562A (en) * 1986-06-03 1994-07-05 Incyte Pharmaceuticals, Inc. Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5196196A (en) * 1986-06-03 1993-03-23 Incyte Pharmaceuticals, Inc. Use of protease nexin-I in wound dressings
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5756094A (en) * 1991-03-27 1998-05-26 Trustees Of The University Of Pennsylvania Methods for stimulating follicular growth
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
IL107578A (en) * 1993-11-11 1998-07-15 Yissum Res Dev Co Topical antibacterial preparation comprising silver sulfadiazine and collagen
MX9708045A (es) * 1995-04-20 1998-03-31 Univ Pennsylvania Composiciones y metodos para regular el crecimiento del cabello.
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
CA2537246A1 (en) * 2003-09-03 2005-03-17 Kringle Pharma Inc. Skin ulcer preventive or curative agent containing human recombinant hgf
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
DE3606265A1 (de) * 1986-02-27 1987-09-03 Roehm Pharma Gmbh Wundauflage auf polysaccharidbasis als traeger therapeutisch wirksamer, nicht-immobilisierter enzyme und mit hoher saugfaehigkeit
US5006252A (en) * 1986-06-03 1991-04-09 Invitron Purified protease nexin
AU6879091A (en) * 1989-10-16 1991-05-16 Invitron Corporation Protease nexin i/dextran sulfate anticoagulant

Also Published As

Publication number Publication date
JP3150338B2 (ja) 2001-03-26
JPH05508148A (ja) 1993-11-18
DE69129071T2 (de) 1998-10-29
EP0556178A4 (en) 1993-04-27
US5112608A (en) 1992-05-12
AU647120B2 (en) 1994-03-17
EP0556178B1 (en) 1998-03-11
DE69129071D1 (de) 1998-04-16
AU7680391A (en) 1991-10-30
CA2079783A1 (en) 1991-10-06
ATE163861T1 (de) 1998-03-15
EP0556178A1 (en) 1993-08-25
WO1991015233A1 (en) 1991-10-17

Similar Documents

Publication Publication Date Title
ES2114887T3 (es) Utilizacion de proteasa nexina-i que induce la cicatrizacion de heridas.
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
ES2040261T3 (es) Procedimiento para preparar acidos 6-fluor-4-oxo-1,4-dihidroquinolina-3-carboxilicos sustituidos y acidos 9-fluor-3-metil-7-oxo-2,3-dihidro-7h-pirido(1,2,3-de)(1,4)benzoxazina-6-carboxilico sustituidos.
GR890100838A (el) Νέα ?εραπευτικώς δραστική ένωσις και μέ?οδος για την παραγωγή της.
ES522310A0 (es) Un metodo de tratar una composicion sustancialmente seca que incluye factor viii de plasma sanguineo.
ES553821A0 (es) Un procedimiento para la preparacion de nuevas azetidinonas sustituidas.
BR9101065A (pt) Lampada fluorescente compacta
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
FI873364A0 (fi) Foerfarande foer framstaellning av ett sytotoxiskt laekemedel.
BR9306683A (pt) Adesivo proteináceo curado com aldeído
ES2039226T3 (es) Procedimiento para preparar composiciones que contienen policarbofil.
GR900100380A (el) Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
FI843409A0 (fi) Fluorometer.
ATE26115T1 (de) Substituierte 8-phenylxanthine.
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
NO944406L (no) Nye 7 e inhibitorer
ES2067822T3 (es) Inhibidores de la fosfolipasa a2 isoprenoide y preparaciones que los contienen.
BG35328A3 (en) Method for preparing imidodisulphamidic derivatives
ES2095068T3 (es) Peroxicarbonatos polimericos y procedimiento para prepararlos.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BG31498A3 (en) Method for obtaining of pyridiliminomethyl benzene derivatives
BG40803A3 (bg) Метод за получаване на арилциклобутилалкиламинови производни
DK448587A (da) Stereoisomer form af visse phenylethanolamniderivater
BR8905745A (pt) Composicao de fragrancia,processo para a preparacao de compostos e uso dos ditos compostos
BG38338A3 (en) Method for preparing 6 alpha- methylhydrocortisonic derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556178

Country of ref document: ES